Literature DB >> 20167686

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.

Irina Barash1, Manish P Ponda, David S Goldfarb, Edward Y Skolnik.   

Abstract

BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) leads to kidney failure in half of those affected. Increased levels of adenosine 3':5'-cyclic monophosphate (cAMP) play a critical role in disease progression in animal models. Water loading, by suppressing arginine vasopressin (AVP)-stimulated cAMP production, is a proposed therapy for ADPKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The effects of acute and sustained water loading on levels of urine osmolality (Uosm) and cAMP in 13 subjects with ADPKD and 10 healthy controls were studied. Uosm and cAMP concentrations were measured before and after water loading.
RESULTS: Urine [cAMP] indexed to Uosm significantly decreased with acute water loading in both groups (58% in controls and 35% in ADPKD). Chronic water loading resulted in a nonsignificant 13% decrease in 24-hour urine cAMP excretion in ADPKD participants, despite an increase in 24-hour urine volume by 64% to 3.14 +/- 0.32 L and decrease in mean Uosm by 46%, to below that of plasma (270 +/- 21 mOsm/L).
CONCLUSIONS: Increased water intake of 3 L per day decreased Uosm in most ADPKD subjects. While urine [cAMP] accurately reflects changes in Uosm during acute water loading in ADPKD subjects, chronic water loading did not lower 24-hour urine cAMP excretion, although subjects with higher baseline [cAMP] (>2 nmol/mg Cr) responded best. Decreases in urine [cAMP] and osmolality are consistent with decreased AVP activity. These results support the need for a larger study to evaluate the effect of chronic water loading on ADPKD progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167686      PMCID: PMC2849694          DOI: 10.2215/CJN.04180609

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

Review 1.  Polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

2.  Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease.

Authors:  G A Tanner; J A Tanner
Journal:  Am J Kidney Dis       Date:  2001-11       Impact factor: 8.860

3.  Dissociation between plasma, urine, and renal papillary cyclic AMP content following vasopressin and DDAVP.

Authors:  M J Bia; S Dewitt; J N Forrest
Journal:  Am J Physiol       Date:  1979-09

4.  cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway.

Authors:  T Yamaguchi; J C Pelling; N T Ramaswamy; J W Eppler; D P Wallace; S Nagao; L A Rome; L P Sullivan; J J Grantham
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

5.  Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.

Authors:  Franck A Belibi; Gail Reif; Darren P Wallace; Tamio Yamaguchi; Lincoln Olsen; Hong Li; George M Helmkamp; Jared J Grantham
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

6.  Oral hypertonic saline causes transient fall of vasopressin in humans.

Authors:  J R Seckl; T D Williams; S L Lightman
Journal:  Am J Physiol       Date:  1986-08

Review 7.  Polycystic kidney disease: new understanding in the pathogenesis.

Authors:  Patricia D Wilson
Journal:  Int J Biochem Cell Biol       Date:  2004-10       Impact factor: 5.085

8.  Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.

Authors:  Tamio Yamaguchi; Shizuko Nagao; Darren P Wallace; Franck A Belibi; Benjamin D Cowley; Jill C Pelling; Jared J Grantham
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

9.  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Xiaofang Wang; Qi Qian; Stefan Somlo; Peter C Harris; Vincent H Gattone
Journal:  Nat Med       Date:  2004-02-29       Impact factor: 53.440

10.  Renal injury is a third hit promoting rapid development of adult polycystic kidney disease.

Authors:  Ayumi Takakura; Leah Contrino; Xiangzhi Zhou; Joseph V Bonventre; Yanping Sun; Benjamin D Humphreys; Jing Zhou
Journal:  Hum Mol Genet       Date:  2009-04-02       Impact factor: 6.150

View more
  24 in total

1.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 2.  Autosomal dominant polycystic kidney disease in children.

Authors:  Melissa A Cadnapaphornchai
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

3.  Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.

Authors:  Ao Li; Yuchen Xu; Song Fan; Jialin Meng; Xufeng Shen; Qian Xiao; Yuan Li; Li Zhang; Xiansheng Zhang; Guanqing Wu; Chaozhao Liang; Dianqing Wu
Journal:  JCI Insight       Date:  2018-03-08

Review 4.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

5.  A case of nephrogenic syndrome of inappropriate antidiuresis caused by carbamazepine.

Authors:  Naoko Sekiya; Midori Awazu
Journal:  CEN Case Rep       Date:  2017-12-27

Review 6.  Effects of dietary interventions on incidence and progression of CKD.

Authors:  Nishank Jain; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2014-10-21       Impact factor: 28.314

7.  Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Akiko Nakajima; Yan Lu; Haruna Kawano; Shigeo Horie; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2015-02-27       Impact factor: 2.801

8.  Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.

Authors:  Osama W Amro; Jessica K Paulus; Farzad Noubary; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

Review 9.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 10.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.